Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective

William E Boden; Marcus D Flather; Deepak L Bhatt

doi:10.1007/s10557-010-6245-9

Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective

William E Boden, Marcus D Flather, Deepak L Bhatt

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

The CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial has spurred debate over subgroup analysis interpretation and prompted renewed consideration of the long-term role of dual aspirin and clopidogrel therapy (DAPT) in patients with established vascular disease.

Original language	English
Pages (from-to)	207-16
Number of pages	10
Journal	Cardiovascular Drugs and Therapy
Volume	24
Issue number	3
DOIs	https://doi.org/10.1007/s10557-010-6245-9
Publication status	Published - Jun 2010

Keywords

Aspirin
Hemorrhage
Humans
Platelet Aggregation Inhibitors
Randomized Controlled Trials as Topic
Retrospective Studies
Risk
Thrombosis
Ticlopidine
Time Factors
Vascular Diseases

Access to Document

10.1007/s10557-010-6245-9

Cite this

@article{8f2888b2e4aa49d3ac6445a963b3cad8,

title = "Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective",

abstract = "The CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial has spurred debate over subgroup analysis interpretation and prompted renewed consideration of the long-term role of dual aspirin and clopidogrel therapy (DAPT) in patients with established vascular disease.",

keywords = "Aspirin, Hemorrhage, Humans, Platelet Aggregation Inhibitors, Randomized Controlled Trials as Topic, Retrospective Studies, Risk, Thrombosis, Ticlopidine, Time Factors, Vascular Diseases",

author = "Boden, {William E} and Flather, {Marcus D} and Bhatt, {Deepak L}",

year = "2010",

month = jun,

doi = "10.1007/s10557-010-6245-9",

language = "English",

volume = "24",

pages = "207--16",

journal = "Cardiovascular Drugs and Therapy",

issn = "0920-3206",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Role of dual antiplatelet therapy in symptomatic patients with established vascular disease

T2 - putting the CHARISMA trial into therapeutic perspective

AU - Boden, William E

AU - Flather, Marcus D

AU - Bhatt, Deepak L

PY - 2010/6

Y1 - 2010/6

N2 - The CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial has spurred debate over subgroup analysis interpretation and prompted renewed consideration of the long-term role of dual aspirin and clopidogrel therapy (DAPT) in patients with established vascular disease.

AB - The CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial has spurred debate over subgroup analysis interpretation and prompted renewed consideration of the long-term role of dual aspirin and clopidogrel therapy (DAPT) in patients with established vascular disease.

KW - Aspirin

KW - Hemorrhage

KW - Humans

KW - Platelet Aggregation Inhibitors

KW - Randomized Controlled Trials as Topic

KW - Retrospective Studies

KW - Risk

KW - Thrombosis

KW - Ticlopidine

KW - Time Factors

KW - Vascular Diseases

U2 - 10.1007/s10557-010-6245-9

DO - 10.1007/s10557-010-6245-9

M3 - Article

C2 - 20593231

VL - 24

SP - 207

EP - 216

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 3

ER -